Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Is oropharyngeal sampling a reliable test to detect SARS-CoV-2?

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Specificity and cross-reactivity of a test for anti-SARS-CoV-2 antibodies - Authors' reply

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Early specialised palliative care: interventions, symptoms, problems

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Rafael Dal-Ré
  • Linda-Gail Bekker
  • Christian Gluud
  • Søren Holm
  • Vivekanand Jha
  • Gregory A Poland
  • Frits R Rosendaal
  • Brigitte Schwarzer-Daum
  • Esperança Sevene
  • Halidou Tinto
  • Teck Chuan Voo
  • Nadarajah Sreeharan
Vis graf over relationer

Large-scale deployment of COVID-19 vaccines will seriously affect the ongoing phases 2 and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates. The effect will be particularly acute in high-income countries where the entire adult or older population could be vaccinated by late 2021. Regrettably, only a small proportion of the population in many low-income and middle-income countries will have access to available vaccines. Sponsors of COVID-19 vaccine candidates currently in phase 2 or initiating phase 3 trials in 2021 should consider continuing the research in countries with limited affordability and availability of COVID-19 vaccines. Several ethical principles must be implemented to ensure the equitable, non-exploitative, and respectful conduct of trials in resource-poor settings. Once sufficient knowledge on the immunogenicity response to COVID-19 vaccines is acquired, non-inferiority immunogenicity trials-comparing the immune response of a vaccine candidate to that of an authorised vaccine-would probably be the most common trial design. Until then, placebo-controlled, double-blind, crossover trials will continue to play a role in the development of new vaccine candidates. WHO or the Council for International Organizations of Medical Sciences should define an ethical framework for the requirements and benefits for trial participants and host communities in resource-poor settings that should require commitment from all vaccine candidate sponsors from high-income countries.

OriginalsprogEngelsk
TidsskriftThe Lancet Infectious Diseases
Vol/bind21
Udgave nummer11
Sider (fra-til)e342-e347
ISSN1473-3099
DOI
StatusUdgivet - nov. 2021

ID: 67052362